Treatment Advances in HR+/HER2- Metastatic Breast Cancer

Nadia Harbeck, MD, PhD; Alessandra Gennari, MD

October 18, 2022

Hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer is the most common breast cancer subtype. Once the disease has metastasized, it is not curable. Nevertheless, significant improvements in overall survival in HR+/HER2- metastatic breast cancer have been achieved in recent clinical trials.

In this panel ReCAP, oncologists Dr Nadia Harbeck and Dr Alessandra Gennari discuss recent updates presented at ESMO 2022 and ASCO 2022 that inform treatment decisions, including data on the CDK4/6 inhibitors abemaciclib, ribociclib, and palbociclib.

They close their commentary by examining antibody-drug conjugates as a second-line treatment option for patients with HR+/HER2- breast cancer. Specifically, they discuss overall survival improvements provided by trastuzumab deruxtecan and sacituzumab govitecan compared with chemotherapy alone.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Treatment Advances in HR+/HER2- Metastatic Breast Cancer - Medscape - Oct 18, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Need a Curbside Consult? Share cases and questions with Physicians on Medscape Consult. Share a Case

Treatment Advances in HR+/HER2- Metastatic Breast Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Experts

Nadia Harbeck, MD, PhD

Alessandra Gennari, MD

Comments

Email This

Feedback